



# Trainee Celebration Day

Friday, April 9, 12 – 3:30 PM ET

<b>12:00 – 12:35</b>		
	<b>Gayathri Devi, PhD, MS</b> Program Director, Duke Consortium for IBC Duke University School of Medicine	<i>Opening Remarks</i>
	<b>Massimo Cristofanilli, MD, FACP</b> Associate Director of Translational Research Robert H Lurie Comprehensive Cancer Center, Northwestern University President of the International Society of Liquid Biopsy (ISLB) President of the Inflammatory Breast Cancer International Consortium (IBC-IC)	<i>Inflammatory Breast Cancer (IBC): The Disease, the Treatment and the Need for a Coordinate Action from the International Consortium</i>
	<b>Anh N. Tran, PhD, MPH</b> Vice Chief of Education, Division of Community Health, Department of Family Medicine & Community Health Duke University School of Medicine	<i>Training Opportunities for Community-Engaged Population Health</i>
<i>Session Q&amp;A</i>		
<b>12:35 – 1:00</b>		
	<b>Alanna Burwell, MPH, PhD Candidate</b> Integrated Biosciences North Carolina Central University	<i>Health Disparities Research in Women</i>
	<b>Scott Sauer, PhD</b> Head of Preclinical Discovery Vujia De Sciences	<i>Preventing Cancer Metastasis &amp; Recurrence by Targeting Metastatic Endurance</i>
<i>Session Q&amp;A</i>		
<b>1:00 – 1:30</b>		
	<b>Eoin McDonnell, PhD</b> CEO and Co-founder Tavros Therapeutics	<i>Discovering Innovative, Targeted Oncology Drugs Using High-Throughput Functional Genomics</i>
	<b>John Davis, MBA</b> Teladoc Health	<i>From the Bench to Business</i>
<i>Session Q&amp;A, Short Break</i>		



<b>1:30 – 2:05</b>	<b>Seayoung Lee, BS Candidate</b> Dept. of Biology Duke University	<i>Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer is Associated with Shorter Survival and Resistance to Chemotherapy</i>
	<b>Gabriela Ortiz Soto, PhD Candidate</b> Cellular and Molecular Biology Universidad Central del Caribe-School of Medicine	<i>Metadherin Positively Regulates Inflammatory Breast Cancer Progression</i>
	<b>Moises Tacam, BS</b> Research Assistant II University of Texas MD Anderson Cancer Center	<i>Evaluating the Efficacy of a Novel Second Generation MELK Inhibitor in IBC and TNBC</i>
<b>2:05 – 2:35</b>	<b>Christophe Van Berckelaer, MD Ob/Gyn</b> University Hospital of Antwerp	<i>The Role Of Infiltrating Immune Cells in the Aggressive Phenotype Of Inflammatory Breast Cancer.</i>
	<b>Katherine Aird, PhD</b> Associate Professor, Department of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine	<i>A Metabolic-Epigenetic Axis Determines Cell Fate Decisions In Ovarian Cancer</i>
		<i>Session Q&amp;A</i>
<b>2:35 – 3:00</b>	<b>Brandi Duff, PharmD</b> Patient Advocate	<i>Musings on Having Inflammatory Breast Cancer</i>
		<i>Final Q&amp;A &amp; Concluding Remarks</i>
<b>3:00 – 3:30</b>		<i>Optional Small Group Discussion</i>